Drug
Pegylated Interferon Alpha 2A
Pegylated Interferon Alpha 2A: highest development phase Phase 2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pegylated Interferon-alpha 2a, 180 mcg/week sc NCT00594880 | Phase 2 | HIV Infections |
Latest
No recent events.
Follow Pegylated Interferon Alpha 2A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.